RENNANO
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

RENNANO Trademark

Serial Number: 79313763 • Registration: 6714941

RENNANO is a trademark filed by Biocytogen Pharmaceuticals (Beijing) Co., Ltd. on February 24, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 31 (Natural Agricultural Products). The application is currently registered and active.

Owner Contact Info

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (12 trademarks)

No.12, Baoshen South Street,

Entity Type: 03

Trademark Details

Filing Date

February 24, 2021

Registration Date

May 3, 2022

Published for Opposition

February 15, 2022

Goods & Services

Vaccines; pharmaceutical preparations for the treatment of immune system related diseases and disorders; medicines for the treatment of cancer; diagnostic preparations for medical purposes; biochemical medicines for the treatment of tumors, infectious diseases, inflammation and autoimmune diseases; medicines for human purposes for the treatment of tumors, infectious diseases, inflammation and autoimmune diseases; drugs for medical purposes for the treatment of tumors, infectious diseases, inflammation and autoimmune diseases; biological preparations for medical purposes for the treatment of tumors, infectious diseases, inflammation and autoimmune diseases; active pharmaceutical ingredients being chemical and biological preparations for pharmaceutical purposes, namely, antibodies for the treatment of human and animal diseases; diagnostic preparations for medical and veterinary purposes; dietetic preparations adapted for medical use; medicines for veterinary purposes for the treatment of tumors, infectious diseases, inflammation and autoimmune diseases

Live trees; live plants; live animals; poultry, live; pigs, live; hamsters, live; live laboratory animals; plant seeds; fodder; litter for animals

Conducting early evaluation in the field of new pharmaceutical products; development of products for others; consulting services in the field of technology development in the fields of pharmaceutical research and development; research and development of new products; pharmaceutical research services; quality control inspection in the field of pharmaceutical research and development; biochemical research and analysis; research and development services in the field of antibodies; medical and scientific research, namely, conducting clinical trials for others; biological research; development of pharmaceutical preparations and medicines; product testing; pharmaceutical products development services; evaluation of pharmaceuticals; technological research, namely, pharmaceutical research

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Mar 25, 2023 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Oct 10, 2022 FINO
GENERIC MADRID TRANSACTION SENT TO IB
Sep 4, 2022 XXSS
GENERIC MADRID TRANSACTION CREATED
Sep 4, 2022 XXCR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Aug 3, 2022 FICR
REGISTERED-PRINCIPAL REGISTER
May 3, 2022 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 15, 2022 NPUB
PUBLISHED FOR OPPOSITION
Feb 15, 2022 PUBO
NOTIFICATION PROCESSED BY IB
Feb 14, 2022 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jan 26, 2022 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jan 26, 2022 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 26, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 8, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 7, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 7, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 7, 2022 TROA
REFUSAL PROCESSED BY IB
Nov 5, 2021 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Oct 8, 2021 RFCS
REFUSAL PROCESSED BY MPU
Oct 8, 2021 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 24, 2021 RFCR
NON-FINAL ACTION WRITTEN
Sep 23, 2021 CNRT
ASSIGNED TO EXAMINER
Sep 19, 2021 DOCK
APPLICATION FILING RECEIPT MAILED
Jul 1, 2021 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 27, 2021 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jun 24, 2021 REPR